Connect with our staff as we participate and present in the following sessions at the 2019 Genitourinary Cancers Symposium
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
11:30 AM-1:00 PM and 5:30 PM-6:30 PM
Poster Session A: Prostate Cancer and Trials in Progress Poster Session A: Prostate Cancer
BOARD B16
Abstract 28: The effect of the timing of biochemical failure after external beam radiotherapy or low-dose-rate brachytherapy for definitive prostate cancer treatment.
First Author: Jay Ciezki, MD
BOARD E2
Abstract 78: Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction).
First Author: Omar Mian, MD, PhD
BOARD E11
Abstract 87: Prospective evaluation of a new patient decision aid to enhance prostate cancer screening decision-making.
First Author: Michael Brooks
BOARD E13
Abstract 89: Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis.
First Author: Lewis Thomas, M.D.
BOARD H12
Abstract 191: Determining androgen inactivation status in prostate cancer by [18F] DHT PET.
First Author: Ziqi Zhu
BOARD M12
Abstract 277: 3βHSD1 immunohistochemistry and HSD3B1 genotype in prostate cancer.
First Author: JJ Zhang, M.D.
12:15 PM-1:45 PM and 5:15 PM-6:15 PM
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers
BOARD C17
Abstract 135: The effect of urologic oncology fellowship training on type and yield of prostate biopsy.
First Author: Molly DeWitt-Foy, MD
BOARD J7
Abstract 436: Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS).
First Author: Iris Sheng, MD
BOARD J8
Abstract 437: Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in patients with urothelial carcinoma (UC) undergoing cystectomy.
First Author: Jaleh Fallah, MD
BOARD K18
Abstract 469: Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
First Author: Lewis Thomas, M.D.
BOARD L10
Abstract 483: Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy.
First Author: Kyle Ericson, MD
7:00 AM-7:55 AM and 12:30 PM-2:00 PM
Poster Session C: Renal Cell Cancer
Trials in Progress Poster Session C: Renal Cell Cancer
BOARD D2
Abstract 541: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian Rini, MD, FACP
BOARD D19
Abstract 558: Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
First Author: Brian Rini, MD, FACP
BOARD F4
Abstract 587: Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).
First Author: Jaleh Fallah, MD
BOARD G9
Abstract 614: Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).
First Author: Brian Rini, MD, FACP
7:55 AM-9:30 AM
Welcome and General Session 7: Key Questions in Localized Kidney Cancer
Risk Stratification After Resection of Localized Disease: Which Model to Use and Why
Brian I. Rini, MD
Cleveland Clinic Taussig Cancer Institute
10:00 AM-11:30 AM
General Session 8: Evolving Management of Metastatic Renal Cell Carcinoma
Abstract 541: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian I. Rini, MD, FACP
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy